Dulaglutide biosimilar - Sunshine Lake Pharma
Alternative Names: 14028 injectionLatest Information Update: 28 Jun 2025
At a glance
- Originator Sunshine Lake Pharma
- Class Antihyperglycaemics; Glucagon-like peptides; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (SC, Injection)
- 08 Jul 2022 Sunshine Lake Pharma completes a phase I clinical trial in Type 2 diabetes mellitus (In volunteers) in China (SC) (NCT05459285)
- 31 May 2022 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in China (SC) (NCT05459285)